Hsu Alice J, Neptune Asha, Adams Constants, Hutton Nancy, Agwu Allison L
From the *Division of Pediatric Pharmacy, Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland; †Howard University College of Medicine, Washington, DC; ‡Medical University of South Carolina, Charleston, South Carolina; §Division of General Pediatrics & Adolescent Medicine, and ¶Division of Infectious Diseases, Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland.
Pediatr Infect Dis J. 2016 Jun;35(6):642-8. doi: 10.1097/INF.0000000000001116.
Antiretroviral (ARV) management in pediatrics is a challenging process in which multiple barriers to optimal therapy can lead to poor clinical outcomes. In a pediatric HIV clinic, we implemented a systematic ARV stewardship program to evaluate ARV regimens and make recommendations for optimization when indicated.
A comprehensive assessment tool was used to screen for issues related to genotypic resistance, virologic/immunologic response, drug-drug interactions, side effects and potential for regimen simplification. The ARV stewardship team (AST) made recommendations to the HIV clinic provider, and followed patients prospectively to assess clinical outcomes at 6 and 12 months.
The most common interventions made by the AST included regimen optimization in patients on suboptimal regimens based on resistance mutations (35.4%), switching to safer ARVs (33.3%) and averting significant drug-drug interactions (10.4%). In patients anticipated to have a change in viral load (VL) as a result of the AST recommendations, we identified a significant benefit in virologic outcomes at 6 and 12 months when recommendations were implemented within 6 months of ARV review. Patients who had recommendations implemented within 6 months had a 7-fold higher probability of achieving a 0.7 log10 reduction in VL by 6 months, and this benefit remained significant after controlling for adherence [adjusted odds ratio: 6.8 (95% confidence interval: 1.03-44.9; P <0.05)].
A systematic ARV stewardship program implemented at a pediatric HIV clinic significantly improved clinical outcomes. ARV stewardship programs can be considered a core strategy for continuous quality improvement in the management of HIV-infected children and adolescents.
儿科抗逆转录病毒(ARV)治疗管理是一个具有挑战性的过程,其中多种阻碍最佳治疗的因素可能导致不良临床结局。在一家儿科HIV诊所,我们实施了一项系统性的ARV管理计划,以评估ARV治疗方案,并在必要时提出优化建议。
使用一种综合评估工具筛查与基因型耐药、病毒学/免疫学反应、药物相互作用、副作用以及简化治疗方案可能性相关的问题。ARV管理团队(AST)向HIV诊所的医护人员提出建议,并对患者进行前瞻性随访,以评估6个月和12个月时的临床结局。
AST做出的最常见干预措施包括根据耐药突变对治疗方案欠佳的患者进行方案优化(35.4%)、换用更安全的ARV药物(33.3%)以及避免严重的药物相互作用(10.4%)。对于预计因AST建议而出现病毒载量(VL)变化的患者,我们发现当在ARV复查后6个月内实施建议时,6个月和12个月时的病毒学结局有显著改善。在6个月内实施建议的患者,到6个月时VL降低0.7 log10的概率高出7倍,在控制依从性后这一益处仍然显著[调整优势比:6.8(95%置信区间:1.03 - 44.9;P <0.05)]。
在儿科HIV诊所实施的系统性ARV管理计划显著改善了临床结局。ARV管理计划可被视为HIV感染儿童和青少年管理中持续质量改进的核心策略。